Bronchodilators are type of variety of drugs that act as an anticholinergic agent, enlarging and relaxing blocked airways in the lungs. Bronchidilators are endogenous in nature and the medications/drugs under this variety of drug are used for the treatment of breathing difficulties such as COPD and asthma. Bronchodilators are mainly used for the treatment of COPD. Ipratropium bromide, the main composition of bronchidilator medication is most efficient in treatment of COPD and asthma. New bronchodilators have slower efficiency of action but longer duration of effect.
- Indacaterol, an emerging bronchodilator, falls under the once-daily ‘long-acting b2-agonist (LABA)’ category. Indacaterol is a fast-acting compound with a more effective action than older drugs Salmeterol and Formoterol.
- Carmoterol and GSK-642444 too fall in the same category of ultra-long acting beta-agonists.
- Long-acting muscarinic antagonist (LAMA) Glycopyrronium, and the LAMA/LABA fixed-dose combination drug variety QVA149 are another example for new emerging long-acting bronchodilator.
- NVA237, another long-acting muscarinic antagonist under the long-acting bronchodilator category is an emerging drug variety for chronic obstructive pulmonary disease.
- β2-adrenoceptor agonists under the long-acting bronchodilator found to have effect and drug efficacy for 24 hour or longer.
- Olodaterol, belongs to inhaled ultra-LABA of long-acting bronchodilator is another emerging drug variety.
Other similar emerging long-acting bronchodilator drugs for treatment of COPD and asthma are; Vilantero, Abediterol, Batenfenterol, Cormoterol, and Milveterol. Most of the emerging long-acting bronchodilators are prepared by Novartis and GlaxoSmithKline. More researches are underway for highly effective long-acting bronchodilators in treatment or COPD and asthma.